Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 4fludarabine phosphate 3fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Cytarabine 2Azacitidine 2venetoclax 1thymoglobulin 1tazemetostat 1romidepsin 1quizartinib 1plerixafor 1glucarpidase 1cc-486 1capmatinib 1aldesleukin 1Zoledronic Acid 1Vincristine 1Transplantation 1Thiotepa 1Spironolactone 1Rituximab 1Rifampin 1Pravastatin 1Polymerase Chain Reaction 1Palliative Care 1Methotrexate 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × quizartinib × Sarcoma × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡